Page 230 - Binder2

Shared Design Philosophy

Across these use cases, oral antibodies offer a new
paradigm in immunotherapy:

• Local delivery at the site of pathogen or antigen
contact
• Reduced systemic exposure, minimizing
immunogenicity and side effects
• Stability in plant matrices, allowing ambient
storage and easy administration
• Format flexibility (sIgA, IgY, nanobodies),
depending on target and route

This isn’t about flooding the system with antibodies.
It’s about putting the right molecule in the right place—
at the right time.

The Immune and Operational Advantage

Because oral antibodies don’t circulate systemically, they
are less likely to provoke anti-drug antibodies—a major
cause of therapeutic failure in IV-administered biologics.
This makes them ideal for:

• Pediatric use
• Prophylactic regimens
• Chronic inflammatory conditions
• First-line deployment in outbreak or low-
infrastructure scenarios

Additionally, because oral antibodies can be formulated
for stability and self-administration, they eliminate many
of the barriers to traditional biologic access: infusion

228